Submit a proposal for an educational session, poster, or management case study. Get involved and present at an ASHP meeting today.
FDA and Novartis on Monday announced the approval of panobinostat, a histone deacetylase (HDAC) inhibitor, for the third-line treatment of multiple myeloma.
Sagent Pharmaceuticals Inc. on Monday announced it was recalling six lots of atracurium besylate 10-mg/mL injection vials because an FDA inspection of the contract
With the start of the 2015 election season at ASHP, the Board of Directors has released guidelines on campaign decorum along with a FAQ.
FDA and The Medicines Company on April 30 announced the approval of Raplixa, a fibrin sealant product, to help control mild-to-moderate bleeding during surgical
FDA on April 29 approved the biologics license application for the recombinant coagulation factor IX product known as Ixinity, by Cangene Corporation.
A recently published report in The BMJ concludes that acetaminophen doesn't do much to relieve low back pain or pain from osteoarthritis of the hip or knee despite
FDA announced Wednesday that pharmacy personnel have misinterpreted the phrase "1 g/0.5 g per vial" on the vial and carton labeling of ceftolozane–tazobactam for
A May 15 Drug Safety Communication from FDA warns that sodium–glucose cotransporter-2 (SGLT2) inhibitors, a recently approved class of antidiabetic medications,